EveryDose included in Pharmaceutical Commerce Magazine

Type 1 and type 2 diabetes affects approximately 422 million people worldwide and 37 million people in the United States according to the World Health Organization (WHO) and Centers for Disease Control (CDC). Managing diabetes successfully requires a multidimensional approach including lifestyle changes, consistent blood glucose monitoring and adherence to complex and often confusing medication regimens. Diabetes often affects people with other existing chronic diseases and depression which complicates their ability to keep track of their daily medications and ultimately control their diseases. In Pharmaceutical Commerce’s Controlling Diabetes: Advances and Adherence, it’s mentioned by Christine Walton of Dr. Reddy’s Laboratories that “the adherence challenge remains a code that has not yet been cracked.” EveryDose’s software engineers beg to differ, literally and figuratively! 

Through behavior-modification tactics, personalized engagement, and predictive analytics, EveryDose’s platform can increase adherence to glucose-lowering meds. The use of digital health solutions like EveryDose certainly make life easier, but do not eliminate the need for intervention and follow-up from a patient’s care team. In fact, EveryDose’s AI chatbot Maxwell identifies reasons for nonadherence within the app then shares that information with the patient’s appropriate clinicians. Follow-ups are now more than just a check in, they are personal, relevant, and resource oriented. Read more about the advancements made and adherence solutions created to uncomplicate controlling diabetes here.